<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981030</url>
  </required_header>
  <id_info>
    <org_study_id>1037</org_study_id>
    <nct_id>NCT02981030</nct_id>
  </id_info>
  <brief_title>Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine</brief_title>
  <official_title>Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine: A Demonstration Study of 800 mcg Buccal Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charitable Foundation Women Health &amp; Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine how a simplified outpatient medical abortion procedure using
      mifepristone and misoprostol, with the option to take mifepristone at a place of woman's
      choosing, works in Ukraine. The investigators intend to demonstrate the efficacy of oral
      administration of 200 mg mifepristone and buccal administration of 800 mcg misoprostol with
      gestations through 70 days, as well as the acceptability of this method.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful abortion</measure>
    <time_frame>2 weeks after mifepristone administration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Abortion, Therapeutic</condition>
  <arm_group>
    <arm_group_label>Simplified medical abortion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Women seeking medical abortion will be offered the option to take mifepristone at home</description>
    <arm_group_label>Simplified medical abortion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.</description>
    <arm_group_label>Simplified medical abortion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have an intrauterine pregnancy consistent with gestational age less than 71 days;

          -  Be able to understand and willing to sign a consent form;

          -  Be eligible for medical abortion according to the clinician's assessment;

          -  Be able to return to the clinic and able to contact study staff or emergency medical
             services, if needed;

          -  Be willing to provide an address and/or telephone number for purposes of follow-up;

          -  Agree to comply with the study procedures and visit schedule.

        Exclusion Criteria:

          -  Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;

          -  Chronic renal failure;

          -  Concurrent long-term corticosteroid therapy;

          -  History of allergy to mifepristone, or misoprostol or another prostaglandin;

          -  History of hemorrhagic disorders or concurrent anticoagulant therapy;

          -  History of inherited porphyrias;

          -  Intrauterine device in place (must be removed before mifepristone is administered).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrida Platais, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamar Tsereteli, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Galyna Maystruk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Charitable Foundation Women Health &amp; Family Planning</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrida Platais, MS</last_name>
    <email>iplatais@gynuity.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lviv Municipal Women's Consultation No. 2</name>
      <address>
        <city>L'viv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Tretyakova</last_name>
    </contact>
    <investigator>
      <last_name>Maria Tretyakova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vinnitsa Regional Clinical Hospital</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inna Kukuruza</last_name>
    </contact>
    <investigator>
      <last_name>Inna Kukuruza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

